Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zabadinostat + geptanolimab
- Development stage
- Unknown
- Lead developer
- IngeneOx Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Zabadinostat + geptanolimab is a combination therapy being investigated for the treatment of advanced hepatocellular carcinoma (HCC), particularly in patients who have become resistant to immune checkpoint inhibitors. Zabadinostat is a histone deacetylase (HDAC) inhibitor that functions as a small molecule immuno-modulator designed to enhance the immune system's ability to recognize and destroy cancer cells. It works by modulating the expression of tumor antigens on cancer cells, making them more visible to the immune system. Geptanolimab is an immune checkpoint inhibitor (ICI) that targets the programmed cell death-1 (PD-1) receptor. The combination is being studied in a randomized Phase 2 clinical trial conducted by the Chinese University of Hong Kong (CUHK).
- Other names
- CXD101 + geptanolimabzabadinostat and geptanolimab
02
Targets
HDAC1 (Histone Deacetylase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on zabadinostat + geptanolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zabadinostat + geptanolimab.